BioVaxys Provides Update on Management Cease Trade Order

VANCOUVER, BC — March 31, 2026 — Leads & Copy —

BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB0) (OTCQB: BVAXF) has provided an update on the management cease trade order (MCTO) granted on March 3, 2026, by the British Columbia Securities Commission (BCSC) under National Policy 12-203 – Management Cease Trade Orders (NP 12-203).

The company announced on March 3, 2026, that it was unable to file its audited annual financial statements for the year ended October 31, 2025, the related management’s discussion and analysis, and its Form 52-109FV1 CEO and CFO certifications of annual filings (collectively, the “Annual Filings”). Under National Instrument 51-102 - Continuous Disclosure Obligations, the Annual Filings were required to be made not later than February 28, 2026.

BioVaxys is working with its auditor, Dale Matheson Carr-Hilton LaBonte LLP, to complete the Annual Filings, which it expects to file as soon as possible. The company anticipates completing the Annual Filings by April 28, 2026, assuming current conditions remain the same.

As a result of the delay in filing the Annual Filings, the company anticipates it will not be in a position to file its interim financial statements for the three months ended January 31, 2025, its management’s discussion and analysis of financial statements for the three months ended January 31, 2025, and related filings (collectively, the “Interim Filings”). Under National Instrument 51-102, the Interim Filings are required to be made not later than April 1, 2026. The company anticipates filing the Interim Filings immediately after the filing of the Annual Filings.

The company confirmed there are no other material changes to the information contained in the Default Announcement. BioVaxys intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports in the form of news releases, for so long as the company remains in default with the Annual Filings and/or Interim Filings.

The company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Annual Filings. BioVaxys also confirmed that, as of the date of this news release, the company is not subject to any insolvency proceedings and there is no other material information concerning the affairs of the company that has not been generally disclosed.

While the MCTO is in effect, the general investing public will continue to be able to trade freely the company’s listed common shares. However, the MCTO prohibits the company’s Chief Executive Officer and Chief Financial Officer from trading securities of the company for so long as the Annual Filings are not filed. Additionally, the company will be prohibited from directly or indirectly issuing or acquiring securities from insiders or employees of the company until such time as the Annual Filings have been made and all continuous disclosure requirements have been met by the company, and the MCTO has been revoked.

BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization for food allergy, and other immunological diseases.

The company's clinical stage pipeline includes maveropepimut-S (MVP-S), based on the DPX™ platform, in phase IIB clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant Ovarian Cancer. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FSE: 5LB0) and in the U.S. on the OTC Markets (OTCQB: BVAXF).

Signed “James Passin”, James Passin, Chief Executive Officer.

Source: BioVaxys Technology Corp.